CHATSWORTH, Calif.--(BUSINESS WIRE)--CHAD Therapeutics, Inc. (AMEX:CTU) announced today that it has commenced mailing its definitive proxy statement to shareholders for approval of its proposed sale of assets related to its oxygen conserving business to Inovo, Inc., a privately held manufacturer of oxygen regulators and conservers based in Naples, Florida, pursuant to an asset purchase agreement dated November 16, 2007. The Company has scheduled a special meeting of shareholders for Thursday, January 31, 2008, at 10:00 a.m. PST at CHAD Therapeutics, Inc, 21622 Plummer Street, Chatsworth, CA, 91311. Shareholders of record as of the close of business on December 24, 2007, will be entitled to vote at the meeting.
